SCHEDULE: BlackRock Discloses Vanda Pharmaceuticals Stake

BlackRock Portfolio Management LLC has filed a Schedule 13G, reporting beneficial ownership of 4.2% of Vanda Pharmaceuticals Inc. common stock as of March 31, 2026.

Summary

• BlackRock Portfolio Management LLC has filed an amendment to its Schedule 13G filing concerning Vanda Pharmaceuticals Inc.
• As of March 31, 2026, BlackRock Portfolio Management LLC beneficially owns 2,508,488 shares of Vanda Pharmaceuticals Inc. common stock.
• This represents 4.2% of the total class of securities.
• The filing indicates that BlackRock Portfolio Management LLC has sole voting power over 2,206,827 shares and sole dispositive power over 2,508,488 shares.
• There is no shared voting or dispositive power reported.
• The filing clarifies that this Schedule 13G reflects securities beneficially owned by certain business units of BlackRock, Inc. and its subsidiaries and affiliates, and does not include securities owned by other business units whose ownership is disaggregated.
• Various persons have the right to receive or direct dividends or proceeds from the sale of Vanda Pharmaceuticals Inc. common stock, but no single person's interest exceeds five percent of the total outstanding shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It is a routine disclosure of beneficial ownership by an institutional investor and does not provide new operational or financial information about the company itself.

Positives

• BlackRock, a significant institutional investor, has disclosed a substantial stake in Vanda Pharmaceuticals Inc., which can be seen as a positive signal of confidence.
• The clear reporting of sole voting and dispositive power indicates direct control over the shares held.

Negatives

• The filing does not contain any negative financial or operational information about Vanda Pharmaceuticals Inc. itself, as it is a disclosure of ownership by BlackRock.

Risks

• The filing does not explicitly mention any risks related to Vanda Pharmaceuticals Inc. or BlackRock's investment.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Vanda Pharmaceuticals Inc. It is a disclosure of beneficial ownership by BlackRock.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for institutional investors like BlackRock when their beneficial ownership of a public company's stock reaches a certain threshold. This filing indicates BlackRock's ongoing investment activity in the biotechnology and pharmaceutical sector, specifically within Vanda Pharmaceuticals Inc.

Stakeholder Impact

• Shareholders: The filing confirms BlackRock's significant stake, which may influence market perception and trading activity. It does not directly impact shareholder rights or dividends.
• Management of Vanda Pharmaceuticals Inc.: The filing is a notification to management about a major shareholder's holdings.
• Other Investors: Provides transparency regarding the ownership structure of Vanda Pharmaceuticals Inc.

Next Steps

• BlackRock will continue to monitor its holdings in Vanda Pharmaceuticals Inc. and may file amendments to this Schedule 13G if there are material changes in its beneficial ownership.
• Vanda Pharmaceuticals Inc. will continue its business operations as usual, with this filing having no direct impact on its operational next steps.

Key Dates

Keywords

Vanda Pharmaceuticals Inc., BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Ownership Disclosure